テネシーにおける消化器がんの臨床試験
テネシー内の拠点で、消化器がんに関する13件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07544589A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
- GSK Investigational Site, Knoxville
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07218926A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07283939Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Henry-Joyce Cancer Clinic, Nashville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06445062Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Sarah Cannon Research Institute, Nashville
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/03更新 · NCT06040541A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/05/27更新 · NCT03093116Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Tennessee Oncology, Chattanooga
- Sarah Cannon Research Institute, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- SCRI Oncology Partners, Nashville
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT07020221ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。